The U.S. Food and Drug Administration on Thursday granted an early approval to S...
FILE PHOTO: The headquarters of the U.S. Food and Drug Administration is seen in Silver Spring, Maryland November 4, 2009. REUTERS/Jason Reed/File Photo
- The U.S. Food and Drug Administration on Thursday granted an early approval to Sarepta Therapeutics Inc’s gene therapy for Duchenne muscular dystrophy . DMD is a rare, genetic disorder that hampers muscle movement mainly in men, affecting one in every 3,500 to 5,000 males.Reporting by Dania Nadeem in Bengaluru; Editing by Sriraj Kalluvila
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Sarepta stock surges more than 20% as FDA finally OKs muscular dystrophy drugSarepta Therapeutics Inc. shares surged in the extended session Thursday after the genetic medicine company said the Food and Drug Administration approved...
Leer más »
Senate confirms Stephen Hahn as new FDA commissionerStephen Hahn is poised to take the helm of the agency amid national concern around youth nicotine use with e-cigarettes and lung injuries connected to illicit vaping products.
Leer más »
Senate confirms Dr. Stephen Hahn as FDA commissionerThe US Senate on Thursday confirmed Dr. Stephen Hahn to be the next commissioner of the US Food and Drug Administration. The Senate vote was 72 to 18.
Leer más »
Senate OKs Trump's FDA nominee despite unclear vaping agendaIn his confirmation hearing last month, Hahn repeatedly sidestepped questions about the fate of the flavor ban.
Leer más »
Sarepta stock surges more than 20% as FDA finally OKs muscular dystrophy drugSarepta Therapeutics Inc. shares surged in the extended session Thursday after the genetic medicine company said the Food and Drug Administration approved...
Leer más »